Search

Your search keyword '"Kłopocka, Maria"' showing total 158 results

Search Constraints

Start Over You searched for: Author "Kłopocka, Maria" Remove constraint Author: "Kłopocka, Maria"
158 results on '"Kłopocka, Maria"'

Search Results

1. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

2. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

3. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

5. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

6. Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study.

9. Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study

10. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

11. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

12. Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study

15. sj-docx-1-tag-10.1177_17562848231151295 – Supplemental material for Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study

16. Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib.

17. Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib

19. 905 DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL

20. Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY

21. Su1762 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: 2 YEARS RESULTS OF THE LIBERTY-CD STUDY

26. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

27. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.

29. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

30. P117 Filgotinib reduces markers of JAK1 signaling in Crohn’s disease: concordance with endoscopy and histopathology

31. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)

33. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

34. Tu1747 INTERIM RESULTS FROM THE RANDOMIZED VERDICT TRIAL TO DETERMINE THE OPTIMAL TREATMENT TARGET IN PATIENTS WITH ULCERATIVE COLITIS

35. Tu1701 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY

36. 1028 SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).

37. Profile of homeless people in emergency departments.

39. P081 Rapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II

40. 772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II

43. Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey

47. 1027 SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY

48. Depressive and anxiety symptoms among patients with inflammatory bowel diseases

49. Possible under-treatment of women in Poland with Crohn’s disease: a subgroup analysis from a prospective multicenter study of the use of anti-TNFs

50. Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis

Catalog

Books, media, physical & digital resources